IVBXF (Innovent Biologics) GF Value Rank: 10 (As of Jul. 26, 2026) — 150% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVBXF Innovent Biologics Inc IVBXF
77 GF Score
Price $10.83
GF Value $12.93
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics GF Value Rank?

Innovent Biologics IVBXF -15.39% 77 GF Value Rank is 10 as of Jul. 26, 2026, which is 150% above its 10-year median of 4.00. GuruFocus rates IVBXF with a GF Score™ of 77/100 and a GF Value™ of $12.93 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Innovent Biologics has the GF Value Rank of 10.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Innovent Biologics GF Value Rank Related Terms

IVBXF vs VRTX, REGN, ALNY: GF Value Rank Comparison

For the Biotechnology subindustry, Innovent Biologics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's GF Value Rank falls into.


IVBXF
77GF Score
Innovent Biologics Inc IVBXF
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 10 mean?
Innovent Biologics (IVBXF) has a GF Value Rank of 10 as of Jul. 26, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Innovent Biologics and its competitors. This is 150% above median its historical median of 4.00. Over the past decade, Innovent Biologics' GF Value Rank has ranged from 2.00 to 10.00.
Is Innovent Biologics' GF Value Rank too high?
Innovent Biologics' current GF Value Rank of 10 is 150% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Innovent Biologics has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' GF Value Rank compare to VRTX and REGN?
Innovent Biologics' GF Value Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Innovent Biologics' own GF Value Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Innovent Biologics and its competitors. Innovent Biologics's current GF Value Rank is 10, which is 150% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (IVBXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.93, compared to a current price of $10.83 — trading 16.2% below its estimated fair value. The current GF Value Rank is 10, which is 150% above median its 10-year median of 4.00. Innovent Biologics' overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Innovent Biologics (IVBXF), the current GF Value Rank is 10 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innovent Biologics (IVBXF) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of $10.83 is trading 16.2% below its estimated GF Value™ of $12.93. GuruFocus considers Innovent Biologics to be Modestly Undervalued.

Key valuation signals for IVBXF:

  • GF Value Rank: 10 (150% above median its 10-year median of 4.00)
  • GF Value™: $12.93 vs. price of $10.83 (16.2% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the IVBXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
77GF Score

Get the complete analysis for IVBXF

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.83
Price
$12.93
GF Value